Company News

February 15, 2023

EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury.

February 08, 2023

EuMentis Therapeutics Inc. Receives $3 Million Award from United States Department of Defense (DoD) to Advance its Novel NMDA Receptor Antagonist for Traumatic Brain Injury.

March 24, 2022

EuMentis Therapeutics, Inc. (“EuMentis” or the “Company”), a clinical-stage pharmaceutical company developing neurocircuit-selective medicines to treat neurodevelopmental disorders, announced today that it will initiate a phase 2 clinical study of EM-221 for the treatment of Tourette Syndrome.

October 27, 2020

February 13, 2020

EuMentis Therapeutics Inc. Announces Company Launch and Focus on Developing Novel Therapeutics to Treat High Value Neurodevelopmental and Neurodegenerative Diseases